Navigation Links
Sangamo BioSciences Announces Presentation of Data on ZFP Therapeutic for Glioblastoma at American Association for Cancer Research (AACR) Meeting
Date:4/15/2008

ZFN Modified Cells Show Glioblastoma Killing in the Presence of

Dexamethasone in Mouse Tumor Model

SAN DIEGO, April 15 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) today announced the presentation of positive data in a mouse tumor model from its ZFP Therapeutic(TM) program for the treatment of glioblastoma multiforme (GBM), a progressive and usually fatal brain cancer. The data were presented in the New Approaches to Biological Therapy Session at the 2008 Annual Meeting of the American Association for Cancer Research (AACR) by Sangamo's collaborator Michael C.V. Jensen, M.D., Associate Chair, Division of Cancer Immunotherapeutics & Tumor Immunology, City of Hope.

"In collaboration with Sangamo, we have successfully generated engineered T-cells that can destroy glioblastoma tumor cells in animals in the presence of glucocorticoids," said Dr. Jensen. "Treatment of recurrent GBM with modified T-cells, an otherwise promising approach for this cancer, is rendered ineffective by the use of glucocorticoids to control inflammation of the brain due to the tumor and surgery. These data show that we have solved that problem and are making significant progress in our efforts to create an 'off-the-shelf' cell-based product for the treatment of GBM. The ZFN(TM)-modification of the glucocorticoid receptor (GR) in our engineered T-cells protects the cells from the effects of glucocorticoids which would normally inhibit T-cell function, and in addition, does not alter their cytolytic or tumor-killing properties."

Dr. Jensen has developed novel chimeric immunoreceptors called "zetakines" that can be engineered into human immune cells to generate a population of cells that can specifically
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Sangamo BioSciences and Sigma-Aldrich Announce Publication of Study Demonstrating Zinc Finger Technology for Rapid Generation of Knock-Out Cell Lines
2. Sangamo BioSciences Reports 2007 Fourth Quarter and Year-End Financial Results
3. Sangamo BioSciences Announces Completion of Enrollment of Phase 2 Clinical Trial of ZFP Therapeutic for Diabetic Neuropathy
4. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
5. Monogram Biosciences Provides Progenics Pharmaceuticals with HIV Assays for Use in Clinical Trials
6. Novel PCT Method Unveiled by Pressure BioSciences, Inc. and Collaborators at the Harvard School of Public Health
7. Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma Viral Load
8. Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodeficiency Virus
9. Neurocrine Biosciences Reports Fourth Quarter and Year-End 2007 Results
10. CeloNova BioSciences Introduces a New Class of Coronary Stent: The CATANIA(TM) Coronary Stent System with NanoThin Polyzene(R)-F
11. CeloNova BioSciences Announces Positive Results from European Study of Embozene(TM) Microspheres for Treatment of Uterine Fibroids
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 29, 2014   Mast Therapeutics, Inc. ... today that Santosh Vetticaden, Chief Medical Officer and ... for personal reasons, in mid-September.  Edwin L. ... Aires Pharmaceuticals, which Mast acquired earlier this year, ... Company,s interim Chief Medical Officer.  Dr. Parsley previously ...
(Date:8/29/2014)... 29, 2014 Research and Markets ... Instrument Industry Report, 2014-2017" report to their offering. ... rising proportion of reimbursement for medical expenses, the Chinese ... its scale presenting a CAGR of 19.2% during 2009-2013. ... product segments of orthopedic instruments in China ...
(Date:8/29/2014)... 2014 Does your doctor know what you,re smoking?  ... recommended marijuana to the over 112,000 currently registered patients under ... of the other roughly 20,300+ active physicians listed with the ... it – even though a poll in February 2014 showed ... have tried it. "With marijuana legalization underway, ...
Breaking Medicine Technology:Mast Therapeutics Announces Management Change 2Mast Therapeutics Announces Management Change 3Mast Therapeutics Announces Management Change 4China Orthopedic Instrument Industry Report, 2014-2017 2Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 2Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 3Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 4
... 10, 2011 MAQUET Cardiovascular, a leading provider ... signed a three-year, dual-source contract with Premier Healthcare ... the Premier membership.  The contract includes the CS300 ... 50cc IABP Catheter, SENSATION® 7Fr. IABP Catheter and ...
... PRINCETON, N.J., Oct. 10, 2011 Pharmasset, Inc. (Nasdaq: ... two treatment arms to the ELECTRON trial of PSI-7977, ... chronic hepatitis C (HCV). The rapid and consistent antiviral ... to date provided the rationale for additional exploratory regimens ...
Cached Medicine Technology:MAQUET Cardiovascular Awarded Three-Year Contract From Premier Healthcare Alliance for Intra-Aortic Balloon Pumps 2MAQUET Cardiovascular Awarded Three-Year Contract From Premier Healthcare Alliance for Intra-Aortic Balloon Pumps 3Pharmasset Announces Further Expansion of ELECTRON Trial in Hepatitis C 2Pharmasset Announces Further Expansion of ELECTRON Trial in Hepatitis C 3Pharmasset Announces Further Expansion of ELECTRON Trial in Hepatitis C 4
(Date:8/30/2014)... Saturday 30 August 2014: A new method ... external defibrillators (AEDs) was presented at ESC Congress today ... predictive method, Paris needs 350 AEDs located in public ... arrest (OHCA). , Dr Dahan said: "Out of hospital ... an annual incidence ranging between 50 and 100 per ...
(Date:8/30/2014)... Colorado (PRWEB) August 31, 2014 According to ... proven step by step holistic system for skin health. It ... has already been tried by more than 138,000 patients from ... by Mike Walden, who says that this method will not ... permanent clear skin. , What makes this program unique ...
(Date:8/30/2014)... 2014 Zensah®, the leader in compression technology ... emerge as a best-seller within golf and tennis. Golfers and ... they enjoy most by using the compression elbow sleeve to ... is a condition that causes pain on the inner side ... attach to the bony bump on the inside of your ...
(Date:8/30/2014)... The Truth about Six Pack Abs is a new method ... shocking foods that can burn belly fat, unique workouts that ... as some motivation secrets for successful fitness. , The author ... trick that can help users reduce junk-food cravings. , ... think, cardio exercise routines are not the best to be ...
(Date:8/30/2014)... 2014 Information supplied by insurance companies ... better prices to consumers in 2014. A group of ... when using the open system for adults at ... to use this year can help the average person ... location and not from medical histories. The finder tool ...
Breaking Medicine News(10 mins):Health News:New method predicts optimal number and location of AEDs 2Health News:Acne No More Review Reveals Unusual Tip to Eliminate Acne Permanently 2Health News:Relieve Golfers and Tennis Elbow Pain with the Zensah® Compression Elbow Sleeve 2Health News:Truth about Six Pack Abs Review Reveals Unique Method to Eliminate Stubborn Stomach Fat 2Health News:Term Life Insurance Rates Now Found Nationally by New Insurer Finder Tool 2
... 6 In a newly-published special supplement, the Journal ... prevent and treat venous thromboembolism (VTE), a major cause ... Lippincott Williams & Wilkins (LWW) is publishing ... that includes both the common medical condition of deep ...
... statement in observance of Pancreatic Cancer Awareness Month , WASHINGTON, ... yet it is the fourth leading cause of death by cancer ... be diagnosed with the disease and more than 35,000 will die ... find a cure for pancreatic cancer researchers have to know more ...
... role in boosting memories -- or forgetting them, researchers say ... remember the first time you smelled a type of flower? ... brain might. , In the study, published online Nov. ... objects to adult study participants. They paired the objects with ...
... small group of patients with severe Graves, eye disease ... vision following treatment with the drug rituximab. Inflammation ... were significantly reduced. The same patients had not previously ... disease. Raymond S. Douglas, M.D., Ph.D., an oculoplastics ...
... TORONTO, On November 6, 2009 Researchers at St. ... fire services across Ontario found that a bystander who attempts ... 50 per cent. But Dr. Laurie Morrison and the research ... per cent of bystanders in Toronto are willing to help, ...
... , COLUMBUS, Ohio, Nov. 6 The Ohio Association of ... health care premiums and less robust benefits if proposals being ... were to become law. , If the reforms proposed by ... in Ohio would increase 60% over five years in the ...
Cached Medicine News:Health News:Journal of Cardiovascular Nursing Urges Policies and Prevention To Reduce Deaths from Venous Thromboembolism 2Health News:Journal of Cardiovascular Nursing Urges Policies and Prevention To Reduce Deaths from Venous Thromboembolism 3Health News:New Smells 'Etched' in Brain: Study 2Health News:Researchers find new way to attack inflammation in Graves' eye disease 2Health News:Less than 1 in 3 Toronto bystanders who witness a cardiac arrest try to help: Study 2Health News:Less than 1 in 3 Toronto bystanders who witness a cardiac arrest try to help: Study 3Health News:Congressional Health Care Reform Proposals Will Make Health Care More Expensive, Less Robust for Ohioans 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: